Table 1.

Ongoing phase III trials, which evaluate the efficacy and safety of selective estrogen receptor degraders as breast cancer adjuvant therapy.

Trial acronym, NCT number and sponsor	Study arms	Intervention duration	Previous ET duration	Patient population	Primary endpoint	CDK4/6 inhibitor and PARP inhibitor treatment	Recruitment status, estimated study completion
lidERA NCT04961996, Hoffmann-La Roche	Giredestrant versus TAM/AI	Giredestrant 5 years (other ET as per investigator discretion)	≤ 12 weeks	Medium to high-risk, stage I–III	IDFS (excluding second non-primary BC)	Prohibited	Recruitment completed, estimated completion in 2033
CAMBRIA-1 NCT05774951, AstraZeneca	Camizestrant versus TAM/AI	5 years	21–63 months	Medium to high-risk, stage I–III	IBCFS	Permitted	Recruiting, estimated completion in 2036
CAMBRIA-2 NCT05952557, AstraZeneca	Camizestrant versus TAM/AI	7 years	≤ 12 weeks	Medium to high-risk, stage I–III	IBCFS	CDK4/6 inhibitor permitted, PARP inhibitor unknown	Recruiting, estimated completion in 2037
EMBER-4 NCT05514054, Eli Lilly and Company	Imlunestrant versus TAM/AI	5 years	2–5 years	Medium to high-risk, stage I–III	IDFS excluding second non-breast primary invasive cancers	Permitted	Recruiting, estimated completion in 2032
ELEGANT NCT06492616, Stemline Therapeutics	Elacestrant versus TAM/AI	5 years	2–5 years	Node-positive, high-risk	IBCFS	Permitted	Recruiting, estimated completion in 2032

Source: Data retrieved from www.clinicaltrials.org.

AI: aromatase inhibitor; BC: breast cancer; ET: endocrine therapy; IBCFS: invasive breast cancer-free survival; IDFS: invasive disease-free survival; NCT: National Clinical Trial; TAM: tamoxifen.